Bayer: Colorectal Neoplasms trials
The registry lists 32 Colorectal Neoplasms studies with Bayer as lead sponsor. 2 are open to participants now and 6 have results posted.
Phase 1 2Phase 2 7Phase 3 4Phase 4 2No phase 17(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06760819Phase 2
- A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid TumorsRecruitingNCT06004245Phase 1
- Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)CompletedNCT04126733Phase 2Results posted
- A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been CompletedCompletedNCT03890731Phase 2Results posted
- Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudyTerminatedNCT01939223Phase 3Results posted
- First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With RegorafenibCompletedNCT01289821Phase 2Results posted
- Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard TherapyCompletedNCT01103323Phase 3Results posted
- Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) SubjectsCompletedNCT00865709Phase 2Results posted
- A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of TreatmentCompletedNCT06137170
- An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United StatesCompletedNCT06029010
- An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World ConditionsCompletedNCT05839951
- An Observational Study, Called RegoFlex EU, to Learn More About the Use of Stivarga at Reduced Doses as Recommended (Flexible Dosing) to Treat People With Metastatic Colorectal Cancer in Real World Settings in EuropeCompletedNCT05551039
- RE-SEARCH Study: A Study to Learn How and in Which Amount Regorafenib is Given in Usual Practice to Patients in Spain: a Study Looking Back at Cases That Have Already Happened When the Study Begins.CompletedNCT04920422
- Effectiveness of Low Dose Aspirin in Decreasing the Chance Getting Stomach and Intestine CancerCompletedNCT04081831
- Study to Develop a Prediction Model to Understand the Effect of Low-dose Aspirin on Cancer That Develops in the Colon and/or the Rectum, Diseases That Affects the Heart or Blood Vessels and Safety Outcomes in European Countries. The Study is Also Called PEACOS Model EUCompletedNCT03904732
- Study to Evaluate How Patients Regard the Benefits and Risks of Low-dose Aspirin for the Prevention of Heart and Blood Vessels Disease and for the Prevention of Cancer of the Colon and RectumCompletedNCT03603366
- EffectiveNess of Low Dose Aspirin in GastrointEstinal Cancer Prevention - TaiwanCompletedNCT03579732
- Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).CompletedNCT03564938Phase 4
- Metastatic Colorectal Cancer Patients With Long-term Response to RegorafenibCompletedNCT03386825
- Stivarga Real Life Evidence in HungaryCompletedNCT02656524
- A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsCompletedNCT02576431Phase 2
- Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal CancerCompletedNCT02465502Phase 2
- Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal CancerCompletedNCT02347852
- Stivarga Regulatory Post-Marketing Surveillance Study in KoreaCompletedNCT02106858
- Safety and Effectiveness of RegorafenibCompletedNCT02042144
- Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard TherapyCompletedNCT01959269
- Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard TherapyCompletedNCT01853319Phase 3
- Regorafenib Post-marketing SurveillanceCompletedNCT01843400
- Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard TherapyCompletedNCT01584830Phase 3
- Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard TherapyNo longer availableNCT01538680
- Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRICompletedNCT00934882Phase 1
- Health Economic Evaluation of Primovist-enhanced Liver MRICompletedNCT00764621Phase 4